A family affected by multiple
myeloma will visit the Abramson
Cancer Center of the University of Pennsylvania as
part of its cross-country jaunt to raise awareness of this
form of cancer. Myeloma, also called multiple myeloma, affects
the production of red cells, white cells, and stem
cells and is the second most common of the blood cancers affecting
an estimated 75,000 people worldwide.
Multiple myeloma survivor, Michael Touhy, and his family including
wife Robin, 14 year-old daughter Ally, 9-year-old son Mikey – and
2 pets – have traveled across the United States this
summer, stopping at cancer centers to talk to survivors and
let others know that thanks to new treatments, multiple myeloma
is becoming a manageable disease.
|WHERE & WHEN:
The “Myeloma Mobile” will pull up in front of
the Biomedical Research Building II/III, located at the University
of Pennsylvania School of Medicine on Curie Blvd.
Biomedical Research Building II/III [map]
Univeristy of Pennsylvania School of Medicine
Curie Blvd. (Osler Dr. and Curie Blvd.)
Philadelphia PA 19104
Saturday, August 11th
10 a.m. – 12 p.m.
Michael Touhy was just 36 when he was told he had an incurable
cancer, multiple myeloma, and five years to live.
Now 42 and in full remission, Mike and his family have taken
to the road in the “Myeloma Mobile” to spread the
word all across the continental US about the novel myeloma
treatments – some of them being pioneered right here
in Philadelphia at the Abramson Cancer Center – that
have kept him alive.
A. Stadtmauer, MD, co-director of
Marrow and Stem Cell Transplant Program at the Abramson
Cancer Center and national leader in the treatment of multiple
myeloma, has helped pioneer new, non-chemotherapy treatments.
These new treatments, which target the mechanisms by which
the cancer cells survive and multiply, rather than attacking all cells
(including healthy ones), are turning myeloma into a manageable,
not fatal, cancer. And not a moment too soon:
- Myeloma – which used to only affect the elderly – is
on the rise as it now affects increasingly younger patients,
like Michael Touhy who was only 36 when he was diagnosed.
- Myeloma, which has an environmental component, was
named as one of the cancers for which September 11, 2001
responders are at risk.
The “Myeloma Mobile” is sponsored by the International
# # #
The Abramson Cancer Center (ACC) of the University
of Pennsylvania is a national
leader in cancer research, patient care, and education. The
pre-eminent position of the Cancer Center is reflected in
its continuous designation as a Comprehensive Cancer Center
by the National Cancer Institute for 30 years, one of 39
such Centers in the United States. The ACC is dedicated to
innovative and compassionate cancer care. The clinical program,
comprised of a dedicated staff of physicians, nurse practitioners,
nurses, social workers, physical therapists, nutritionists
and patient support specialists, currently sees over 50,000
outpatient visits, 3400 inpatient admissions, and provides
over 25,000 chemotherapy treatments, and more than 65,000
radiation treatments annually. Not only is the ACC dedicated
to providing state-of-the-art cancer care, the latest forms
of cancer prevention, diagnosis, and treatment are available
to our patients through clinical themes that developed in
the relentless pursuit to eliminate the pain and suffering
from cancer. In addition, the ACC is home to the 300 research
scientists who work relentlessly to determine the pathogenesis
of cancer. Together, the faculty is committed to improving
the prevention, diagnosis and treatment of cancer.
PENN Medicine is
a $3.5 billion enterprise dedicated to the related missions
of medical education, biomedical research, and excellence in
patient care. PENN Medicine consists of the University of Pennsylvania
School of Medicine (founded in 1765 as the nation's first medical
school) and the University of Pennsylvania Health System.
Penn's School of Medicine is currently ranked #3 in the
nation in U.S.News & World Report's survey of top research-oriented
medical schools; and, according to most recent data from the
National Institutes of Health, received over $379 million in
NIH research funds in the 2006 fiscal year. Supporting 1,400
fulltime faculty and 700 students, the School of Medicine is
recognized worldwide for its superior education and training
of the next generation of physician-scientists and leaders of
The University of Pennsylvania Health System includes
three hospitals — its flagship hospital, the
Hospital of the University of Pennsylvania, rated one of the
nation’s “Honor Roll” hospitals by U.S.News & World
Report; Pennsylvania Hospital, the nation's first hospital; and
Penn Presbyterian Medical Center — a faculty practice
plan; a primary-care provider network; two multispecialty satellite
facilities; and home care and hospice.
Penn Medicine is one of the world's leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System, which together form a $6.7 billion enterprise.
The Perelman School of Medicine has been ranked among the top five medical schools in the United States for the past 20 years, according to U.S. News & World Report's survey of research-oriented medical schools. The School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $392 million awarded in the 2016 fiscal year.
The University of Pennsylvania Health System's patient care facilities include: The Hospital of the University of Pennsylvania and Penn Presbyterian Medical Center -- which are recognized as one of the nation's top "Honor Roll" hospitals by U.S. News & World Report -- Chester County Hospital; Lancaster General Health; Penn Wissahickon Hospice; and Pennsylvania Hospital -- the nation's first hospital, founded in 1751. Additional affiliated inpatient care facilities and services throughout the Philadelphia region include Good Shepherd Penn Partners, a partnership between Good Shepherd Rehabilitation Network and Penn Medicine.
Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2016, Penn Medicine provided $393 million to benefit our community.